Glaucoma is a general grouping of eye diseases that impact the optic nerve, resulting in progressive vision loss. According to the NIH National Eye Institute, currently, over 2.7 million Americans suffer from glaucoma, and approximately 11 million are projected to be afflicted by 2050. For many years, clinicians have struggled to find an efficacious treatment for glaucoma. To date, first-line drugs have had limited effectiveness due to progression of the disease or low patient compliance, and conventional surgical methods lacked the efficacy to produce a long-term cure. In the late 1990s, researchers began thinking about non-traditional approaches for
Professor and inventor Michael Demetriou has been studying immune-related diseases and cancers long before founding GlyTR Therapeutics in 2015. Prof. Demetriou’s research focuses on aberrant protein glycosylation that occurs in diseased cells. Glycosylation, the addition of sugars or glycans to proteins and other biomolecules, is an important method cells use to define the structure, function, and transportation of the molecule.